Daily tadalafil and heart health: why researchers are looking beyond ED

Daily tadalafil is attracting attention beyond the bedroom, and there is a credible reason for that interest. Researchers studying men with erectile dysfunction have found encouraging associations between tadalafil use and cardiovascular outcomes. Those findings deserve a closer look.

The research is promising, but it has not established that taking tadalafil 5 mg every day prevents heart attacks. Understanding that distinction makes the conversation more useful. You can take the emerging science seriously while choosing treatment for benefits that are already supported.

Why an ED medication belongs in the heart-health conversation

Erections depend partly on healthy blood vessels. Vascular erectile dysfunction and cardiovascular disease share risk factors, including diabetes, smoking, and high blood pressure. An erection change can therefore create an opportunity to look at more than sexual performance.

The Princeton IV expert consensus describes ED as a cardiovascular risk marker and recommends assessing cardiovascular risk in men with vascular ED. It also discusses the possible heart-related benefits of PDE5 inhibitors, the medication class that includes tadalafil. Princeton IV consensus.

Tadalafil helps preserve a chemical signal called cGMP, which supports smooth-muscle relaxation and penile blood flow during sexual stimulation. That vascular biology helps explain the research interest. A plausible mechanism, however, needs clinical outcomes to establish a preventive benefit. Tadalafil prescribing information.

The cardiovascular finding that deserves attention

A 2024 study compared US insurance records for 8,156 men with ED who had tadalafil prescriptions and 21,012 men with ED who had no PDE5-inhibitor prescriptions. After adjustment, tadalafil exposure was associated with a 19% lower hazard of major adverse cardiovascular events, or MACE: hazard ratio 0.81, with a 95% confidence interval of 0.70–0.94.

Here, MACE combined cardiovascular death with events including heart attack, coronary revascularization, unstable angina, heart failure, and stroke. The headline figure describes that combined outcome, not heart attacks alone.

This was an observational claims study, not randomized treatment. Prescription records cannot confirm tablets were taken, and differences in health or behavior may remain despite statistical adjustment. It also did not isolate a 5 mg daily regimen. Sanofi funded the research; the authors reported that the sponsor did not participate in data collection, analysis, or manuscript drafting. Original 2024 study.

The finding is a reason to investigate further. It is stronger than a biological theory, while still leaving the key clinical question open: would assigning comparable men to tadalafil actually prevent cardiovascular events?

What randomized research adds

The RECOGITO trial explored a more specific question. Researchers randomized 122 adults with type 2 diabetes and cardiac remodeling to tadalafil 20 mg daily or placebo for 20 weeks. Cardiac remodeling means changes in the heart’s structure or function.

Certain imaging measures of heart-muscle mechanics improved in men receiving tadalafil, with different responses between men and women. Randomization strengthens that finding within the studied population, but the endpoints were measurements of cardiac function. The trial did not establish fewer heart attacks or longer life, and its dose was four times the 5 mg daily ED regimen. RECOGITO trial.

A heart scan can reveal a useful treatment signal. Whether that signal translates into fewer serious events requires a different kind of study, with enough participants and follow-up to measure those events.

Why the particular heart condition matters

Tadalafil should not be treated as beneficial for every cardiovascular diagnosis. The PASSION trial studied people with heart failure with preserved ejection fraction and a specific form of pulmonary hypertension, targeting 40 mg daily. It stopped early because of medication supply disruption, after enrolling 125 participants.

The trial did not demonstrate benefit on its combined hospitalization-and-death outcome and found a concerning mortality signal. Small numbers and early termination limit interpretation. This was a very different population and regimen from low-dose ED treatment, but it shows why findings cannot be generalized across heart conditions. PASSION trial.

Is daily tadalafil the new baby aspirin?

That comparison goes beyond the evidence. Tadalafil has not been established as a substitute for aspirin or other cardiovascular treatment.

Even aspirin is no longer a blanket recommendation for otherwise healthy adults as they age. The US Preventive Services Task Force recommends an individualized decision about starting aspirin for primary prevention in adults aged 40–59 with at least a 10% estimated ten-year cardiovascular risk. The potential net benefit is small and must be weighed against bleeding. It recommends against starting aspirin for primary prevention at age 60 or older. USPSTF recommendation.

Those recommendations concern preventing a first cardiovascular event. Aspirin prescribed after a heart attack, stroke, or other established disease is a separate situation. Do not replace or stop prescribed aspirin because of the tadalafil research. Ask the clinician managing your cardiovascular care how each medication fits your own history.

Use the conversation to understand your health

You do not need to wait for a definitive prevention trial to make an ED appointment worthwhile. Bring changes in erections into a broader discussion of blood pressure, cholesterol, diabetes, smoking, physical activity, and family history. Princeton IV supports cardiovascular risk assessment as part of caring for men with vascular ED. Consensus recommendations.

Useful questions include:

• Could my erection changes have a vascular component?
• Is my current cardiovascular risk assessment up to date?
• Does my health history make sexual activity or ED medication a concern?
• If tadalafil fits my ED care, what favors daily or on-demand treatment?

You are asking two connected questions: how to improve sexual function and how to understand cardiovascular risk. Both deserve a clear answer, even when they lead to different parts of your care team.

The interaction to take seriously

Tadalafil must not be combined with nitrate medicines (including nitroglycerin), nitrite “poppers,” or riociguat. These combinations can dangerously lower blood pressure. Other blood-pressure medicines and alpha-blockers also need review. With daily use, tadalafil remains in your system between doses, so an interaction is not limited to the hours around sex.

If chest pain occurs after taking tadalafil, seek immediate medical attention and tell the treating team when you last took it. Do not self-treat with nitroglycerin. Prescribing information.

For a fuller discussion of side effects and suitability, read Is daily tadalafil safe?.

Choosing a daily plan for the right reason

The strongest current reason to consider daily tadalafil through ED care is the treatment of erections, with a schedule that can reduce the need to plan medication around intimacy. The cardiovascular research adds an interesting question for your clinician, rather than a promised extra benefit.

Compare daily and on-demand tadalafil, or explore the daily tadalafil ED option. If urinary symptoms are also part of the picture, our guide to tadalafil for ED and enlarged-prostate symptoms explains that separate, established use and the evaluation it needs.